466 related articles for article (PubMed ID: 32463390)
21. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
Steenbeek MP; van Bommel MHD; intHout J; Peterson CB; Simons M; Roes KCB; Kets M; Norquist BM; Swisher EM; Hermens RPMG; ; Lu KH; de Hullu JA
Int J Gynecol Cancer; 2023 Jun; 33(6):982-987. PubMed ID: 37045546
[TBL] [Abstract][Full Text] [Related]
22. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
[TBL] [Abstract][Full Text] [Related]
23. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract][Full Text] [Related]
24. Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Kang OJ; Lee SW; Kim JH; Park JY; Suh DS; Kim DY; Kim JH; Kim YM; Kim YT
Int J Gynecol Cancer; 2023 Nov; 33(11):1743-1749. PubMed ID: 37541685
[TBL] [Abstract][Full Text] [Related]
25. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
26. [Early epithelial lesions in prophylactic annexectomies in patients at high risk of ovarian cancer: Report of a series of 93 cases].
Selmes G; Ferron G; Filleron T; Querleu D; Mery E
Gynecol Obstet Fertil; 2015 Oct; 43(10):659-64. PubMed ID: 26433315
[TBL] [Abstract][Full Text] [Related]
27. Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
Kuji S; Kondo H; Ohara T; Deura I; Tozawa-Ono A; Migita O; Kawamoto H; Tsugawa K; Chosokabe M; Koike J; Maeda I; Suzuki N
Jpn J Clin Oncol; 2021 Mar; 51(3):492-497. PubMed ID: 33377156
[TBL] [Abstract][Full Text] [Related]
28. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
Powell CB; Chen LM; McLennan J; Crawford B; Zaloudek C; Rabban JT; Moore DH; Ziegler J
Int J Gynecol Cancer; 2011 Jul; 21(5):846-51. PubMed ID: 21670699
[TBL] [Abstract][Full Text] [Related]
29. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
30. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
Cass I; Walts AE; Barbuto D; Lester J; Karlan B
Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
[TBL] [Abstract][Full Text] [Related]
31. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR
Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014
[TBL] [Abstract][Full Text] [Related]
32. The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
Rudaitis V; Mikliusas V; Januska G; Jukna P; Mickys U; Janavicius R
Eur J Obstet Gynecol Reprod Biol; 2020 Apr; 247():26-31. PubMed ID: 32059136
[TBL] [Abstract][Full Text] [Related]
33. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
34. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
[TBL] [Abstract][Full Text] [Related]
35. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
Finch A; Shaw P; Rosen B; Murphy J; Narod SA; Colgan TJ
Gynecol Oncol; 2006 Jan; 100(1):58-64. PubMed ID: 16137750
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
37. Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
Ricciardi E; Tomao F; Aletti G; Bazzurini L; Bocciolone L; Boveri S; Landoni F; Lapresa MT; Maruccio M; Parma G; Peccatori F; Petrella MC; Zanagnolo V; Colombo N; Maggioni A
Anticancer Res; 2017 Sep; 37(9):5241-5248. PubMed ID: 28870960
[TBL] [Abstract][Full Text] [Related]
38. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
Crosbie EJ; Flaum N; Harkness EF; Clayton RD; Holland C; Martin-Hirsch P; Wood N; Keating P; Woodward ER; Lalloo F; Donnai P; Edmondson RJ; Evans DG
Int J Cancer; 2021 Mar; 148(5):1155-1163. PubMed ID: 33152107
[TBL] [Abstract][Full Text] [Related]
39. Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report.
Grandi G; Caroli M; Alboni C; Cortesi L; Toss A; Barbieri E; Botticelli L; Facchinetti F
Fam Cancer; 2020 Oct; 19(4):291-295. PubMed ID: 32328861
[TBL] [Abstract][Full Text] [Related]
40. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
